The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or relapsed acute lymphoblastic leukemia (ALL) patients. However, a limited efficacy of bortezomib alone has been reported. A terminal pro-apoptotic endoplasmic reticulum (ER) stress/unfolded protein response (UPR) is one of the several mechanisms of bortezomib-induced apoptosis. Recently, it has been documented that UPR disruption could be considered a selective anti-leukemia therapy. CX-4945, a potent casein kinase (CK) 2 inhibitor, has been found to induce apoptotic cell death in T-ALL preclinical models, via perturbation of ER/UPR pathway. In this study, we analyzed in T- and B-ALL preclinical settings, the molecular mechanisms of synergistic apoptotic...
Background Bortezomib has been successfully used in the treatment of multiple myeloma and has been p...
Development of resistance and relapse remains a major challenge for acute lymphoblastic leukemia (AL...
Bortezomib (VELCADE™, formerly known as PS-341) is a selective and potent inhibitor of the proteasom...
The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or relapsed ac...
The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or relapsed ac...
The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or relapsed ac...
The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or relapsed ac...
Introduction. The proteasome inhibitor bortezomib is a new treatment option for patients with refrac...
ption for patients with refractory or relapsed ALL, particularly when used in combination with conve...
Constitutively active casein kinase 2 (CK2) signaling is a common feature of T-cell acute lymphoblas...
Constitutively active casein kinase 2 (CK2) signaling is a common feature of T-cell acute lymphoblas...
Bortezomib has been successfully used in the treatment of multiple myeloma and has been proposed as ...
CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on bortezom...
CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on bortezom...
<div><p>CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on ...
Background Bortezomib has been successfully used in the treatment of multiple myeloma and has been p...
Development of resistance and relapse remains a major challenge for acute lymphoblastic leukemia (AL...
Bortezomib (VELCADE™, formerly known as PS-341) is a selective and potent inhibitor of the proteasom...
The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or relapsed ac...
The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or relapsed ac...
The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or relapsed ac...
The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or relapsed ac...
Introduction. The proteasome inhibitor bortezomib is a new treatment option for patients with refrac...
ption for patients with refractory or relapsed ALL, particularly when used in combination with conve...
Constitutively active casein kinase 2 (CK2) signaling is a common feature of T-cell acute lymphoblas...
Constitutively active casein kinase 2 (CK2) signaling is a common feature of T-cell acute lymphoblas...
Bortezomib has been successfully used in the treatment of multiple myeloma and has been proposed as ...
CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on bortezom...
CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on bortezom...
<div><p>CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on ...
Background Bortezomib has been successfully used in the treatment of multiple myeloma and has been p...
Development of resistance and relapse remains a major challenge for acute lymphoblastic leukemia (AL...
Bortezomib (VELCADE™, formerly known as PS-341) is a selective and potent inhibitor of the proteasom...